Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Large Volume Increase – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw unusually-strong trading volume on Thursday . Approximately 2,928,793 shares traded hands during trading, an increase of 114% from the previous session’s volume of 1,366,514 shares.The stock last traded at $10.2820 and had previously closed at $9.94.

Analyst Ratings Changes

Several equities analysts have weighed in on BAYRY shares. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Finally, Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Bayer Aktiengesellschaft has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The firm’s fifty day moving average price is $11.15 and its 200 day moving average price is $11.28. The company has a current ratio of 1.01, a quick ratio of 0.63 and a debt-to-equity ratio of 1.22. The firm has a market capitalization of $40.48 billion, a PE ratio of -16.09, a PEG ratio of 3.30 and a beta of 0.59.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. The business had revenue of $15.73 billion for the quarter, compared to analysts’ expectations of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, research analysts anticipate that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.